Quantcast
Last updated on April 20, 2014 at 8:28 EDT

Latest Head and neck cancer Stories

2013-06-19 08:30:28

Commercial Launch of MyCare(TM) Chemotherapy Exposure Optimization Tests Initiated Through Saladax Biomedical Laboratories BETHLEHEM, Pa., June 19, 2013 /PRNewswire/ -- Saladax Biomedical, Inc., a privately held company developing novel diagnostic tests that help physicians to optimize a patient's exposure to chemotherapy, today announced the U.S. launch of the MyCare(TM) portfolio of exposure optimization tests. The MyCare portfolio is comprised of simple blood tests that provide...

Inexpensive Blood Test Reveals HPV Presence, Potential Cancer Risk
2013-06-18 18:30:30

Brett Smith for redOrbit.com — Your Universe Online Earlier this month, actor Michael Douglas raised the prospect of oral sex leading to throat cancer through the transmission of the human papillomavirus (HPV), a virus known to cause the disease in some individuals. According to a new study from a team of international researchers in the Journal of Clinical Oncology, blood tests can be used to detect the presence of the virus via the body´s production of telltale antibodies...

2013-06-18 13:52:00

-A protein called Nanog helps the renewal of healthy embryonic stem cells. -This study shows that Nanog also promotes cancer stem cell proliferation in head and neck cancer and shows how it promotes their growth. -The findings could lead to new, novel treatments for head and neck cancer. A new study led by researchers at The Ohio State University Comprehensive Cancer Center — Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC—James) has...

2013-06-18 10:32:00

Researchers have found that antibodies against the human papillomavirus (HPV) may help identify individuals who are at greatly increased risk of HPV-related cancer of the oropharynx, which is a portion of the throat that contains the tonsils. In their study, at least 1 in 3 individuals with oropharyngeal cancer had antibodies to HPV, compared to fewer than 1 in 100 individuals without cancer.  When present, these antibodies were detectable many years before the onset of disease. These...

2013-06-03 08:27:40

PRINCETON, N.J., June 3, 2013 /PRNewswire/ -- Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a clinical stage biopharmaceutical company, announced today that its SGX942 development program for the treatment of oral mucositis as a result of radiation and/or chemotherapy treatment in head and neck cancer patients has received "Fast Track" designation from the US Food and Drug Administration (FDA). Fast track is a designation that the FDA reserves for a drug intended to treat a...

2013-06-02 23:15:07

Mount Sinai researchers to present landmark studies at American Society of Clinical Oncology meeting. New York, NY (PRWEB) June 01, 2013 Icahn School of Medicine at Mount Sinai researchers will present several landmark studies at the 2013 American Society of Clinical Oncology (ASCO) meeting May 31-June 4, 2013 in Chicago, including data on the likelihood of spousal human papillomavirus (HPV) oral infection, new gene signatures in melanoma, and issues with high readmission rates after cancer...

2013-05-22 08:27:21

CALGARY, May 22, 2013 /PRNewswire/ - Oncolytics Biotech Inc. ("Oncolytics") (TSX:ONC, NASDAQ:ONCY) today announced preliminary results from its U.S. Phase 2 clinical trial in patients with metastatic melanoma using intravenous administration of REOLYSIN(®) in combination with carboplatin and paclitaxel (REO 020). The Principal Investigator is Dr. Devalingam Mahalingam, M.D., Ph.D., MRCP(UK), MRCP(I), clinical investigator in GI/thoracic oncology and drug development at the Cancer...

2013-05-21 08:30:41

IASIS MEDICAL Sees Substantial Opportunity In Offering IsoRay's Entire Product Line RICHLAND, Wash., May 21, 2013 /PRNewswire/ -- IsoRay, Inc. (AMEX: ISR), (http://www.isoray.com/), announced today that it has entered into an exclusive international distribution agreement with IASIS Medical for the sale of IsoRay's complete product line in Greece. IsoRay is a medical technology company and innovator in seed brachytherapy and medical radioisotope applications for brain cancer, lung...

2013-05-02 23:15:21

Invado Pharmaceuticals announced that Cleveland Clinic Cancer Clinic presented positive clinical data on NeutraSal at ONS World Congress Meeting in Washington DC. The data suggested that NeutraSal is more effective than salt and soda rinses in reducing oral toxicities in head and neck cancer patients. Pomona, NY (PRWEB) May 02, 2013 Invado Pharmaceuticals announced that Jean Hamker, RN of the Cleveland Clinic Taussig Cancer Institute presented data from a NeutraSal study at last week's ONS...

2013-04-17 04:21:42

Throat cancers on the rise due to epidemic of HPV infection TORONTO, April 17, 2013 /CNW/ - Researchers in London, Ontario, are conducting a first-ever clinical trial to determine which treatment option gives patients with throat cancers the best quality of life. These cancers are dramatically on the rise due to the epidemic of HPV (human papilloma virus) infection. Surgeon Dr Anthony Nichols and radiation oncologist Dr David Palma at the Lawson Research Centre have received a...